In phase 2 #ClinicalTrial EA1211/DIRECT, researchers are using an #imaging test called a FDG-PET/CT scan to try to better predict response to therapy for patients with #HER2positive #BreastCancer. Learn more: bit.ly/EA1211

In the #ComboMATCH Study, researchers are testing if genetically-matched drug combinations will be more effective than single drugs for certain patients with #cancer. Learn more: bit.ly/ComboMATCH #PrecisionMedicine #ClinicalTrial

#ICYMI: Steven Schild MD Mayo Clinic .Christine Bestvina UChicago Medicine lead Alliance for Clinical Trials in Oncology A082002, a trial for patients with #metastatic non-small cell #lungcancer who are PD-L1 negative. To learn more about this trial, visit bit.ly/Alliance-A0820… #NCI #NCTN #NSCLCsm

Cancer Trials Support Unit Bi-Monthly Broadcast is now available to notify registered members of recent CTSU announcements and trial updates. Please visit ctsu.org, log in and click on the Broadcast/Newsletter tab.

The EAF223/GABLE clinical study is testing different imaging techniques that could help make better predictions about #BrainCancer progression. Learn more here: bit.ly/gable-trial cc: Duke Radiology, Glioblastoma Foundation, GBM Foundation

#ClinicalTrial EAA173/DETER-SMM, led by Natalie Callander of UW Health | Carbone Cancer Center, is a randomized phase 3 trial for patients with smoldering #MultipleMyeloma (#SMM) and high-risk features. Learn more here: bit.ly/eaa173detersmm #mmsm #BloodCancer

The EA3202 clinical study is comparing three possible treatment approaches for patients with advanced-stage #HeadAndNeckCancer to see which one helps patients live the longest. Learn more: bit.ly/ea3202-study #HNCA #HNCASM

#ClinicalTrial EA7211/STRASS 2, led in the US by Ken Cardona, is the second randomized study ever performed in retroperitoneal soft tissue sarcoma & is enrolling patients in the US, Europe, Canada, Australia, New Zealand, & Japan! bit.ly/EA7211 EORTC Richard Riedel

S2015 (#NCT00352222) Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma was reactivated on 01/09/25. View full memorandum in Protocol Updates on CTSU.

EA1211/DIRECT aims to help doctors make better (more personalized) decisions around treatment for #patients with #HER2positive #BreastCancer. Consider learning more about this phase 2 #clinicaltrial if you have HER2-positive breast cancer. For more info: bit.ly/EA1211

.Shishir K. Maithel of Winship Cancer Institute of Emory University is leading EA2197/OPT-IN, a #ClinicalTrial for patients with incidentally discovered stage 2-3 #GallbladderCancer. Find more information here: bit.ly/EA2197 #gicsm

#ICYMI - .@stuchman1 UNC Lineberger leads Alliance for Clinical Trials in Oncology A062102, a trial that compares iberdomide maintenance therapy to disease monitoring to improve survival in pts who have received idecabtagene vicleucel for multiple #myeloma: bit.ly/Alliance-A0621… #mmsm Multiple Myeloma Hub #NCI #NCTN

S2212 is an SWOG Cancer Research Network non-inferiority trial of shorter anthracycline-free chemo-immunotherapy in patients w early-stage #TNBC. Collects PROs to compare fatigue, other QoL measures. SWOG.org/clinical-trial… QoL Co-PIs: Lynn Henry U-M Rogel Cancer Center Michelle Loch, MD LSU Health New Orleans

#ClinicalTrial EAQ222CD/CostCOM, led by Gelareh Sadigh, MD, is testing the effectiveness of cost communication and financial navigation in patients with #cancer. If you have any newly diagnosed #SolidCancer, you may be able to participate. bit.ly/EAQ222CD

10347 (#NCT04652960) A Phase I Study with an Expansion Cohort of Duvelisib and Nivolumab in Mycosis Fungoides (MF) and Sézary Syndrome (SS) is closed to accrual effective 12/24/24. View the full memorandum in Protocol Updates on the CTSU members’ homepage.

EA2212 (#NCT05836584) Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric & Gastroesophageal Junction Cancer is closed to accrual effective 12/4/24. View the full memorandum in Protocol Updates on the CTSU members’ homepage.

WF2304-A172401 (#NCT06418204) Complementary Options for Symptom Management In Cancer: Assessing Benefits and Harms of Cannabis & Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics was activated on 1/15/24.

A022004 (#NCT05710406) Randomized Trial of Consolidation Targeted Adjuvant Therapy w/ Encorafenib & Cetuximab v. Usual Care for Patients w/ Stage II/III BRAF V600E Colon Cancer is closed to accrual effective 12/20/24. View full memorandum in Protocol Updates on the CTSU homepage.

EA2201 (#NCT04751370) A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma is closed to accrual effective 01/14/25. View the full memorandum in Protocol Updates on the CTSU members’ homepage.

S1800E (#NCT06616584) Randomized Phase II/III Study of Docetaxel & Ramucirumab w/w/o Cemiplimab for Participants Previously Treated w/ Platinum-Based Chemo & Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer has been approved for trial pre-activation.